S63845 |
S63845 : BH3 mimetic inhibitor of MCL1
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| MCL1 |
|
|
BH3 mimetic
up to 1 uM
Selectivity
In Vitro Selectivity Assessment
Potency: Ki - BCL2 >10,000 nM, BCLXL >10,000 nM
Potency Assay Off-Target:
FP assay
Selectivity Assessment Description:
<strong>Outside Target Family:</strong> S63845 had little activity in BCL2 or BCLXL-dependen ...
In Cell Selectivity Assessment
Potency Assay Off-Target:
S63845 had little activity in BCL2 or BCLXL-dependent H146 cells in apoptosis assays.
Potency Cellular
In Vitro
MCL1
Mode of Action: BH3 mimetic
Structure-Activity-Relationship data available? No
In Vivo Validations
SCID and C57BL/6 mice
Dose: 25 mg/kg, Reviewer suggested dose: 6.25-25 mg/Kg IV
Route of delivery:
Intravenous
Organ of interest (O):
Xenografts, various
Target engagement assay:
In several xengraft models hematological and solid tumors, S63845 had anti-tumor activity. At the maximum dose (60 mg/kg), S63845 led to marked reduction in erythocytes.
Reference: --
Chemical Information
| Molecular Formula | C39H37ClF4N6O6S |
| SMILEs | Cc1c(-c2c(-c3ccc(F)o3)sc3ncnc(O[C@H](Cc4ccccc4OCc4ccnn4CC(F)(F)F)C(=O)O)c23)ccc(OCCN2CCN(C)CC2)c1Cl |
| InChI | InChI=1S/C39H37ClF4N6O6S/c1-23-26(7-8-28(34(23)40)53-18-17-49-15-13-48(2)14-16-49)32-33-36(45-22-46-37(33)57-35(32)29-9-10-31(41)55-29)56-30(38(51)52)19-24-5-3-4-6-27(24)54-20-25-11-12-47-50(25)21-39(42,43)44/h3-12,22,30H,13-21H2,1-2H3,(H,51,52)/t30-/m1/s1 |
| Molecular weight | 828.21 Da |
| AlogP | 7.757920000000009 |
| HBond acceptors | 12 |
| HBond donors | 1 |
| Atoms | 94 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.